Insider · CIK 0001706301

Noonberg Sarah B.

Reports to the SEC for 5 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001706301

Forms 4 and 5

Insider transactions

36 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-20	NGNENeurogene Inc. · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+12.1K sh	—	—	12,050
2025-06-12	NGNENeurogene Inc. · Non-Qualified Stock Option (right to buy)A Award	Director	AAward	+12.1K sh	—	—	12,050
2025-06-06	MGXMetagenomi Therapeutics, Inc.S Sale	Chief Medical Officer	SSale	−5,239 sh	$1.75	−$9,168.25	109,135
2025-04-01	MGXMetagenomi Therapeutics, Inc.A Award	Chief Medical Officer	AAward	+14K sh	—	—	114,374
2025-04-01	MGXMetagenomi Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Medical Officer	AAward	+84K sh	—	—	84,000
2024-06-18	MARINUS PHARMACEUTICALS, INC.A Award	Director	AAward	+2,300 sh	—	—	14,100
2024-06-18	MARINUS PHARMACEUTICALS, INC.Stock Option (Right to Buy)A Award	Director	AAward	+10.5K sh	—	—	10,450
2024-06-14	NGNENeurogene Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+7,700 sh	—	—	7,700
2024-04-01	MGXMetagenomi Therapeutics, Inc.A Award	Chief Medical Officer	AAward	+57.8K sh	—	—	100,374
2024-04-01	MGXMetagenomi Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Medical Officer	AAward	+243K sh	—	—	242,875
2024-01-18	MARINUS PHARMACEUTICALS, INC.A Award	Director	AAward	+4,600 sh	—	—	11,800
2024-01-18	MARINUS PHARMACEUTICALS, INC.Stock Option (Right to Buy)A Award	Director	AAward	+20.9K sh	—	—	20,900
2024-01-16	NGNENeurogene Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15.4K sh	—	—	15,400
2023-06-08	NGNENeurogene Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2023-05-16	MARINUS PHARMACEUTICALS, INC.A Award	Director	AAward	+7,200 sh	—	—	7,200
2023-05-16	MARINUS PHARMACEUTICALS, INC.Stock Option (Right to Buy)A Award	Director	AAward	+32.4K sh	—	—	32,400
2023-01-16	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Director	AAward	+30K sh	—	—	30,000
2022-05-26	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Director	AAward	+20K sh	—	—	20,000
2022-05-12	NGNENeurogene Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2021-05-27	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Director	AAward	+18K sh	—	—	18,000
2021-05-11	NGNENeurogene Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2021-02-11	PTGXProtagonist Therapeutics, IncA Award	Director	AAward	+3,700 sh	$6.98	+$25.8K	3,700
2021-02-11	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−3,700 sh	$25.09	−$92.8K	0
2021-02-11	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−3,700 sh	—	—	3,600
2021-02-10	PTGXProtagonist Therapeutics, IncA Award	Director	AAward	+4,700 sh	$6.98	+$32.8K	4,700
2021-02-10	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−4,300 sh	$25.42	−$109K	400
2021-02-10	PTGXProtagonist Therapeutics, IncS Sale	Director	SSale	−400 sh	$26.04	−$10.4K	0
2021-02-10	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)M Exercise/Conversion	Director	MExercise/Conversion	−4,700 sh	—	—	7,300
2020-05-28	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Director	AAward	+15K sh	—	—	15,000
2020-05-05	NGNENeurogene Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2019-10-10	NGNENeurogene Inc. · Stock Option (right to buy)A Award	Director	AAward	+22K sh	—	—	22,000
2019-06-07	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Director	AAward	+12K sh	—	—	12,000
2018-05-29	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Director	AAward	+12K sh	—	—	12,000
2017-12-15	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Director	AAward	+24K sh	—	—	24,000
2017-12-15	PTGXProtagonist Therapeutics, Inc · Stock Option (right to buy)A Award	Director	AAward	+24K sh	—	—	24,000
2017-05-16	PRTAPROTHENA CORP PUBLIC LTD CO · Stock Option (right to buy)A Award	Chief Medical Officer	AAward	+100K sh	—	—	100,000

Recent filings

Accepted (ET)
Feb 244
Noonberg Sarah B.0001706301-26-000002
SEC(opens sec.gov)
Jun 134
Noonberg Sarah B.0001404644-25-000064
SEC(opens sec.gov)
Jun 94
Noonberg Sarah B.0000950170-25-083952
SEC(opens sec.gov)
Apr 34
Noonberg Sarah B.0000950170-25-050098
SEC(opens sec.gov)
Jun 204
Noonberg Sarah B.0001415889-24-017641
SEC(opens sec.gov)
Jun 174
Noonberg Sarah B.0001404644-24-000068
SEC(opens sec.gov)
Apr 34
Noonberg Sarah B.0000950170-24-041527
SEC(opens sec.gov)
Jan 194
Noonberg Sarah B.0001415889-24-001604
SEC(opens sec.gov)
Jan 184
Noonberg Sarah B.0000950170-24-005537
SEC(opens sec.gov)
Jun 94
Noonberg Sarah B.0001209191-23-035861
SEC(opens sec.gov)
May 174
Noonberg Sarah B.0001415889-23-008244
SEC(opens sec.gov)
Jan 184
Noonberg Sarah B.0001104659-23-004734
SEC(opens sec.gov)
May 274
Noonberg Sarah B.0001104659-22-065863
SEC(opens sec.gov)
May 164
Noonberg Sarah B.0001209191-22-029324
SEC(opens sec.gov)
May 284
Noonberg Sarah B.0001209191-21-036663
SEC(opens sec.gov)

Companies

Address

C/O NEUROGENE INC. 535 W 24TH STREET, 5TH FLOOR

NEW YORK, NY, 10011